P8A:SGX
Cordlife Group Ltd
0,12 SGD
0,00%
(0,00) 1 D.
10-12, 09:49:20 GMT+8 · SGD
search
Visi simboliai
| Simbolis | Kaina | Keisti | Pokytis, % |
|---|
insights_autoGeneruojamos svarbiausios „P8A“ įžvalgos...
Rinkos kapitalizacija
32,37 mln.
Vid. kiekis
1,32 tūkst.
Apimtis
0,00
52 sav. aukšta
0,26 SGD
52 sav. žema
0,10 SGD
Pajamos iš vienos akcijos
−0,04 SGD
Neapmokėtos akcijos
267,53 mln.
Darbuotojų skaičius
111
Rinkos kapitalizacija
32,37 mln.
Vid. kiekis
1,32 tūkst.
Apimtis
0,00
52 sav. aukšta
0,26 SGD
52 sav. žema
0,10 SGD
Pajamos iš vienos akcijos
−0,04 SGD
Neapmokėtos akcijos
267,53 mln.
Darbuotojų skaičius
111
Naujienų istorijos
Iš žiniatinklio šaltinių ir naujienų partnerių
vz.lt
·
prieš 24 minutes
JAV rinkų apžvalga: Volstritui atsigaunant, „Dow“ indeksas prekybą baigė gerokai pakilęs
StreetInsider
·
prieš 6 minutes
Global S&P Futures mixed in premarket
The Daily News | Texas' Oldest Newspaper
·
prieš 35 minutes
FILE PHOTO: Traders work on the floor of the New York Stock Exchange (NYSE) in New York City
Opening Bell Daily
·
prieš 34 minutes
Stock Market Outlook: Stock pickers are lagging the index
Profilis
Cordlife Group Limited, is a consumer health company incorporated in May 2001 and a provider of cord blood and cord lining banking services in Asia. Cordlife has been listed on the mainboard of SGX since March 2012.
Cordlife Group owns the largest network of cord blood banks in Asia with full stem cell processing and storage facilities in six markets including Singapore, Hong Kong, India, Indonesia, and the Philippines. Beyond cord blood and cord lining banking, Cordlife offers diagnostics services, particularly for the mother and child segment, including urine-based newborn metabolic screening, non-invasive prenatal testing, paediatric vision screening and family genetic screening services.
Cordlife's stem cell processing and storage facilities in Singapore, Hong Kong, India, Indonesia, the Philippines and Malaysia were accredited by AABB until 2024 when its accreditation was withdrawn.
In November 2023, the Ministry of Health of Singapore revealed that Cordlife Group had exposed cryopreserved cord blood units at suboptimal temperatures, damaging the cord blood units belonging to at least 2,150 clients and rendering them unsuitable for stem cell transplant purposes. Wikipedia
Apie „Cordlife Group Ltd“
Generalinis direktoriusYiu Pang Fai
Darbuotojai111
Įkurta2001-05-02
Pagrindinė būstinė-
SektoriusHealth care provider
Svetainėcordlife.com